Malaysia Next Generation Sequencing Market (2026-2036)
The Malaysia next generation sequencing market is expected to reach USD 145.28 million by 2036 from an estimated USD 47.62 million in 2026, at a CAGR of 11.8% during the forecast period from 2026 to 2036. The market was valued at USD 42.60 million in 2025.
- Published
- Sep 2026
- Pages
- 141
- Format
- PDF + Excel
- Report ID
- MR-2174
- Base year
- 2025
- 2025 · BASELINE
- $42.6M
- 2036
- $145.3M
- CAGR 2026–2036
- 11.8%
2025 baseline · 2026–2036 forecast at 11.8% CAGR · hover a bar for the value
Key highlights
The Malaysia next generation sequencing market is projected to reach USD 145.28 million by 2036 from an estimated USD 47.62 million in 2026, growing at a CAGR of 11.8% during the forecast period from 2026 to 2036.
The growth of the market is supported by the exceptionally high burden of inherited haemoglobin disorders, rising cancer incidence, the expansion of national genomics initiatives, and increasing demand for precision medicine.
Approximately one in four Malaysians carries a haemoglobin abnormality, creating substantial demand for genetic screening and molecular testing.
Studies conducted in Malaysia have demonstrated the ability of sequencing technologies to identify genetic variants that may be missed by established conventional testing methods.
The MyGenom project completed its first phase with more than 2, 400 genomes sequenced and is expected to support further expansion of population genomics capabilities in Malaysia.
The second phase of the national genome programme is expected to expand sequencing activity and strengthen the country's genomic data resources.
The commercial sequencing and outsourced services segment is expected to account for the largest share of the market in 2026.
Data analysis and bioinformatics is expected to register the fastest growth among offeriNGS during the forecast period.
Clinical applications are expected to account for the largest share of the market in 2026, supported by the growing use of sequencing in oncology, reproductive health, rare diseases, inherited disorders, and other clinical applications.
Hospitals, clinical and reference laboratories are expected to account for the largest share of the market among end users and are also expected to register the fastest growth during the forecast period.
The market is consolidated, with leading positions held by international sequencing and life science companies, including Illumina, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., Agilent Technologies, Inc., and Oxford Nanopore Technologies plc.
Report summary
| Particulars | Details |
|---|---|
| Forecast Period | 2026 to 2036 |
| Historical Year | 2024 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| CAGR | 11.8% |
| Format | PDF, Excel & Cloud Portal · 141 pages |
| Market Size in 2025 | USD 42.60 Million |
| Market Size in 2026 | USD 47.62 Million |
| Market Size in 2036 | USD 145.28 Million |
| Segments Covered | By Offering, Application, and End User |
| Country Covered | Malaysia |
| Key Companies | Illumina, Inc.; Thermo Fisher Scientific Inc.; QIAGEN N.V.; Agilent Technologies, Inc.; F. Hoffmann La Roche Ltd.; Revvity, Inc.; Pacific Biosciences of California, Inc.; Danaher Corporation; Oxford Nanopore Technologies plc; MGI Tech Co., Ltd.; BGI Genomics Co., Ltd.; Eurofins Scientific SE; Novogene Co., Ltd. |
Report overview
Segments covered: offering, application, end user.
Next generation sequencing comprises a group of high throughput technologies that determine the sequence of nucleotides across multiple DNA or RNA fragments simultaneously. The technology enables the analysis of targeted gene panels, whole exomes, and whole genomes and is increasingly used across clinical diagnostics, oncology, inherited diseases, reproductive health, infectious disease surveillance, drug discovery, agriculture, and animal research.
The Malaysia next generation sequencing market comprises revenues generated from sample preparation products, sequencing systems and consumables, data analysis and bioinformatics solutions, and commercial sequencing and outsourced services supplied to organizations operating within Malaysia.
The Malaysia next generation sequencing market is expected to reach USD 145.28 million by 2036 from an estimated USD 47.62 million in 2026, at a CAGR of 11.8% during the forecast period from 2026 to 2036. The market was valued at USD 42.60 million in 2025.
Malaysia's genomics ecosystem is being strengthened by national investments in population genomics, precision medicine, and biotechnology. The MyGenom project represents the country's first large scale population genomics initiative. The first phase of the programme was completed in 2026 with more than 2,400 Malaysian genomes sequenced, while the second phase is targeting a cumulative total of 10,000 genomes. The expansion of the programme is expected to increase demand across the complete sequencing workflow, including sample preparation, sequencing consumables, data storage, variant analysis, and bioinformatics services. The market is also supported by the country's substantial burden of inherited genetic disorders. According to published epidemiological studies cited in the report, approximately one in four Malaysians carries one of the prevalent haemoglobin abnormalities. Malaysia's National Thalassaemia Screening Programme already operates at significant volumes, with a single screening centre at Hospital Raja Perempuan Zainab II analysing 13,721 blood samples collected from high school students participating in the national programme. This creates an established pool of screening and confirmatory testing where advanced genomic technologies can gradually expand their role.
Cancer is another important source of demand for molecular diagnostics and precision medicine. According to the Malaysian National Cancer Registry, 168,822 cancer cases were recorded between 2017 and 2021, while more than 60% of cases were diagnosed at stage three or four. The large proportion of patients presenting with advanced disease increases the clinical importance of molecular characterization and supports the use of genomic technologies for treatment selection and precision oncology.
At the same time, the structure of the Malaysian market continues to influence how sequencing services are delivered. A substantial proportion of demand is met through commercial and outsourced service providers, including providers located in Singapore, China, and other regional centres. As domestic sequencing infrastructure expands, Malaysia is expected to gradually strengthen its in country capacity, particularly in population genomics and bioinformatics.
Market dynamics
8 factors across 3 forcesExceptionally High Burden of Inherited Haemoglobin Disorders
The high burden of inherited haemoglobin disorders is one of the most important factors supporting the growth of the Malaysia next generation sequencing market. According to published epidemiological studies cited in the report, approximately one in four Malaysians carries one of the prevalent haemoglobin abnormalities, including alpha thalassaemia, beta thalassaemia, haemoglobin E, delta beta thalassaemia, and haemoglobin Constant Spring.
This burden is addressed through the National Thalassaemia Screening Programme, which includes cascade screening of families of known cases and carriers and targeted voluntary screening of adolescents and young adults, particularly before marriage. The programme is principally delivered through schools and creates recurring testing demand because every new birth cohort generates a new population requiring screening.
The scale of the programme is evident from a single centre study conducted at Hospital Raja Perempuan Zainab II, which analysed 13,721 blood samples collected from high school students participating in the national programme. Beyond initial carrier identification, at risk couples require confirmatory genotyping, while affected pregnancies may require prenatal diagnosis. These applications create opportunities for sequencing technologies to expand beyond conventional haematological screening and into molecular characterization.
Demonstrated Diagnostic Superiority of Sequencing in Established Screening Applications
The adoption of next generation sequencing is also supported by evidence generated within Malaysian healthcare institutions. A study conducted at Hospital Universiti Sains Malaysia applied a targeted sequencing panel covering the HBA1, HBA2, and HBB genes to 14 confirmed thalassaemia cases that had previously been characterized using multiplex amplification refractory mutation system and gap polymerase chain reaction methods.
The sequencing panel identified clinically relevant variants that had not been detected by conventional methods, including an additional beta globin promoter variant, HBA2 mutations, non deletional alpha thalassaemia, and alpha triplication. These findings demonstrate the potential of sequencing to provide greater diagnostic resolution in applications where conventional tests may not capture the complete spectrum of genetic variants. Malaysia's population diversity further strengthens the need for broader genomic approaches. The country's population includes Malay, Chinese, Indian, and indigenous communities in Sabah and Sarawak, creating a genetic variant spectrum that may not always be completely characterized by targeted assays developed using data from other populations.
Completion and Expansion of the National Genome Programme
The completion and planned expansion of the MyGenom project are important factors supporting the growth of Malaysia's next generation sequencing market. The first phase was completed in 2026 and sequenced more than 2,400 genomes from participants selected to represent the ethnic diversity of the Malaysian population.
The second phase is targeting a cumulative total of 10,000 genomes, representing approximately one in every 3,300 people in the population. The expansion would represent a substantial increase in sequencing activity compared with the first phase and is expected to generate demand across the complete genomic workflow.
Population scale sequencing programmes require sample collection, DNA extraction, library preparation, sequencing reagents, flow cells, data storage, alignment, variant calling, and annotation. As a result, the programme creates demand across multiple market segments rather than supporting only the sale of sequencing instruments.
The National Biotechnology Policy 2.0 also provides a broader policy framework for the development of omics technologies and precision medicine. Under Flagship Program 4, biologics, omics technologies, and targeted therapies have been identified as important tools for improving health outcomes through precision and personalized medicine.
Table of contents
10 chapters · 185 sections · 141 pages · click to expandSegmental analysis
| Segment | Largest share (2026) | Fastest growth (2026–2036) |
|---|---|---|
| By Offering | Offering: Commercial Sequencing and Outsourced Services | While Data Analysis and Bioinformatics |
| Other segments | Commercial sequencing and outsourced services | Data analysis and bioinformatics |
| By Application | Clinical | — |
| By End User | Hospitals, Clinical and Reference Laboratories | — |
By Offering
- Commercial Sequencing and Outsourced Services to Hold the Largest Share in 2026, While Data Analysis and Bioinformatics Registers the Fastest Growth
- By Offering: Commercial Sequencing and Outsourced Services to Hold the Largest Share in 2026, While Data Analysis and Bioinformatics Registers the Fastest Growth
- The Malaysia next generation sequencing market is segmented into sample preparation, sequencing, data analysis and bioinformatics, and commercial sequencing and outsourced services.
Other segments
- The commercial sequencing and outsourced services segment is expected to account for the largest share of the market in 2026.
- Its strong position reflects the significant proportion of Malaysian demand served by commercial providers on behalf of institutions that do not operate their own sequencing infrastructure.
- The data analysis and bioinformatics segment is expected to register the fastest growth during the forecast period, with a CAGR of 13.4%.
- The increasing volume of genomic information generated through clinical and research activities is expected to create greater demand for genomic data processing and interpretation capabilities.
By Application
- Clinical Applications to Hold the Largest Share and Register the Fastest Growth
- Clinical applications are expected to account for the largest share of the market in 2026.
- The segment is supported by the growing use of sequencing in oncology, non invasive prenatal testing, reproductive health, infectious diseases, rare diseases, and other clinical applications.
- The clinical applications segment is also expected to register strong growth during the forecast period, supported by the increasing adoption of precision medicine and molecular diagnostics.
By End User
- Hospitals, clinical and reference laboratories are expected to account for the largest share of the market in 2026.
- The segment is also expected to register the fastest growth among end users, supported by the increasing adoption of sequencing technologies for clinical diagnostics and precision medicine.
- Academic and research institutes represent another important source of demand, particularly through national genomics programmes and biomedical research activities.
Competitive landscape
The Malaysia next generation sequencing market is consolidated and is led by international sequencing and life science companies. Illumina, Inc. holds the leading position in the market, followed by Thermo Fisher Scientific Inc., QIAGEN N.V., Agilent Technologies, Inc., and Oxford Nanopore Technologies plc.
Other prominent companies operating in the market include F. Hoffmann La Roche Ltd., Revvity, Inc., Pacific Biosciences of California, Inc., Danaher Corporation, MGI Tech Co., Ltd., BGI Genomics Co., Ltd., Eurofins Scientific SE, Novogene Co., Ltd., and local distributors and sequencing service providers.
The competitive environment is shaped by sequencing platform installations, institutional relationships, national genomics programmes, product portfolios, distribution capabilities, commercial sequencing services, and the ability to provide integrated workflows.
Companies are focusing on product development, acquisitions, partnerships, expansions, and technology integration to strengthen their positions in the genomics market.
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- QIAGEN N.V.
- Agilent Technologies, Inc.
- F. Hoffmann La Roche Ltd.
- Revvity, Inc.
- Pacific Biosciences of California, Inc.
- Danaher Corporation
- Oxford Nanopore Technologies plc
- MGI Tech Co., Ltd.
- BGI Genomics Co., Ltd.
- Eurofins Scientific SE
- Novogene Co., Ltd
Frequently asked questions
The Malaysia next generation sequencing market is estimated at USD 47.62 million in 2026.
Cite this report
Meticulous Research. (2026). Malaysia Next Generation Sequencing Market - Opportunity Analysis and Industry Forecast (2026-2036) (Report No. MR-2174). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/malaysia-next-generation-sequencing-market-6857